Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 18 Results

Title
Intervention Indication Therapeutic Area Year Actions
Adstiladrin for high-grade, BCG unresponsive non-muscle-invasive bladder cancer Adstiladrin (Nadofaragene firadenovec; rAd-IFN/Syn3; Instiladrin) Bladder cancer Urological Cancer 2019 View  |  Download
Atezolizumab for muscle-invasive urothelial carcinoma –adjuvant Atezolizumab (Tecentriq; MPDL3280A) Bladder cancer Urological Cancer 2019 View  |  Download
Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer – first line Atezolizumab (Tecentriq; MPDL3280A) Urothelial cancer Urological Cancer 2020 View  |  Download
Avatrombopag for chemotherapy induced thrombocytopenia in patients with nonhaematological cancers Avatrombopag (Doptelet; E5501; avatrombopag maleate) Chemotherapy-induced thrombocytopenia Female Reproductive Cancer , Haematology , Lung and Respiratory Cancer , Toxicology , Urological Cancer 2020 View  |  Download
Avelumab in addition to best supportive care for locally advanced or metastatic urothelial cancer Avelumab (Bavencio; MSB-0010718C) Bladder cancer Urological Cancer 2019 View  |  Download
Durvalumab (Imfinzi) for locally advanced or metastatic urothelial bladder cancer – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2017 View  |  Download
Durvalumab in combination with tremelimumab and chemotherapy for unresectable, locally advanced or metastatic urothelial cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Bladder cancer Urological Cancer 2020 View  |  Download
Durvalumab in combination with Tremelimumab for locally advanced or metastatic urothelial bladder cancer – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Bladder cancer Urological Cancer 2017 View  |  Download
Durvalumab with Bacillus Calmette-Guerin for treating non-muscle invasive bladder cancer Bacillus Calmette-Guerin (BCG; BCG Tokyo-172; OncoTICE) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2022 View  |  Download
Enfortumab vedotin for locally advanced or metastatic urothelial cancer Enfortumab vedotin (ASG-22ME; Padcev) Urothelial cancer Urological Cancer 2020 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications